Marker Therapeutics (MRKR) AI Stock Analysis

• Market Cap: $14.62M
• Dividend Yield: N/A
• Average Volume (3M): 2.36M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.70
• Revenue Growth: 44.55%
• EPS Growth: -17.92%
• Country: US
• Employees: 5
• Sector: Healthcare
• Sector Strength: 53
• Industry: Biotechnology
• EPS (TTM): -0.29
• Shares Outstanding: 12,938,910
• 10 Day Avg. Volume: 140,753
• 30 Day Avg. Volume: 2,364,235
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.65
• Enterprise Value/Revenue: 1.77
• Enterprise Value/Gross Profit: -2.37
• Enterprise Value/Ebitda: -1.14
• 1Y Price Target: $8.00
• Price Target Upside: 561.16% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 44 Neutral
• Price Target: ―

Marker Therapeutics is positioned in the biotechnology industry, characterized by high potential but also significant risks. The company exhibits strong revenue growth but faces challenges with profitability and cash flow. Technical indicators present a mixed outlook, with some potential for price reversals. The valuation reflects typical industry dynamics, favoring growth over profitability. Investors should be cautious, focusing on the company's ability to manage cash flow and improve operational efficiencies to support future growth.

Positive Factors

Clinical Data

Analyst maintains a BUY rating and $8 price target on Marker based on the expectation for continued positive clinical data for MT-601.

Manufacturing Collaboration

The collaboration with Cellipont lowers manufacturing risk, and allows for easier future expansion for Marker's MT-601.

Market Opportunity

Marker estimates a market opportunity of approximately $1.7B for relapsed lymphoma patients after CAR-T therapy.

Negative Factors

Funding

MRKR secured more than $13 million in non-dilutive funding in 2024 to advance its lead product MT-601.

Private Placement

The company announced a $16.1 million private placement to support the clinical advancements of its Phase 1 APOLLO study.

Regulatory Risk

Cellipont, a leading Contract Development and Manufacturing Organization (CDMO), will manufacture MT-601 in a more effective and consistent manner vs Baylor for the pivotal study, reducing regulatory risk, and boosting chances of success.

Marker Therapeutics Business Overview & Revenue Model

Company Description

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing TPIV100/110, a peptide-based immunotherapeutic vaccines for the treatment of breast and ovarian cancer cells; and TPIV200, which is in Phase 2 clinical trial for the treatment of breast and ovarian cancers. The company was founded in 1999 and is headquartered in Houston, Texas.

How the Company Makes Money

Marker Therapeutics generates revenue primarily through partnerships, collaborations, and licensing agreements with other biotechnology and pharmaceutical companies. These collaborations often involve upfront payments, milestone payments based on the achievement of specific clinical or regulatory objectives, and royalties on future product sales. Additionally, the company may receive funding from grants and research agreements to support the development of its therapeutic candidates. As a clinical-stage company, Marker Therapeutics does not yet generate revenue from product sales, as its products are still undergoing clinical trials and have not yet received regulatory approval for commercialization.

Marker Therapeutics Financial Statement Overview

Summary

Marker Therapeutics shows promising revenue growth but struggles with profitability and cash flow management. The strong cash position provides a buffer, yet the company must focus on improving operational efficiencies and reducing losses to enhance financial health and attract sustainable investment.

Income Statement

Marker Therapeutics has demonstrated consistent revenue growth over the years, culminating in a significant increase in TTM (Trailing-Twelve-Months) revenue. However, this growth is overshadowed by substantial net losses and negative EBIT and EBITDA margins, indicating persistent profitability challenges.

Balance Sheet

The company maintains a strong cash position with zero debt as of the latest report, which enhances its financial stability. However, the negative equity ratio over time and significant net losses are concerning, reflecting a need for improved operational efficiency.

Cash Flow

Marker Therapeutics is experiencing negative operating and free cash flow, indicating cash burn which is common in early-stage biotechs. The positive financing cash flow suggests external funding reliance, which could pose future financial risks if not managed properly.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	5.39M	6.59M	3.31M	9.01M	1.24M	466.79K
Gross Profit	-4.03M	-6.88M	-7.11M	5.32M	-1.92M	-18.41M
EBITDA	-8.38M	-4.53M	-11.27M	-19.79M	-36.31M	-27.63M
Net Income	-14.61M	-10.73M	-8.24M	-29.93M	-41.88M	-28.71M
Balance Sheet
Total Assets	14.77M	22.02M	17.13M	34.42M	68.14M	45.61M
Cash, Cash Equivalents and Short-Term Investments	10.46M	19.19M	15.11M	11.78M	42.35M	21.35M
Total Debt	0.00	0.00	0.00	7.62M	11.87M	12.26M
Total Liabilities	4.28M	3.46M	3.07M	14.82M	24.15M	18.27M
Stockholders Equity	10.49M	18.56M	14.05M	19.60M	43.99M	27.34M
Cash Flow
Free Cash Flow	-10.88M	-10.91M	-16.44M	-31.92M	-30.41M	-29.29M
Operating Cash Flow	-10.88M	-10.91M	-16.44M	-26.97M	-27.28M	-18.86M
Investing Cash Flow	0.00	0.00	18.66M	-4.95M	-3.13M	-10.43M
Financing Cash Flow	14.90M	14.99M	1.11M	202.13K	52.56M	6.74M

Marker Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.21
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MRKR, the sentiment is Negative. The current price of 1.21 is below the 20-day moving average (MA) of 1.29, below the 50-day MA of 1.47, and below the 200-day MA of 1.96, indicating a bearish trend. The MACD of -0.09 indicates Positive momentum. The RSI at 41.58 is Neutral, neither overbought nor oversold. The STOCH value of 30.30 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MRKR.

Marker Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	60 Neutral	HK$19.34B	4.28	-1.43%	3.28%	13.32%	-14.38%
ADXN	58 Neutral	$13.37M	0.70	-162.42%	―	-82.24%	―
MBRX	44 Neutral	$18.05M	―	-503.80%	―	―	60.64%
MRKR	44 Neutral	$14.62M	―	-144.68%	―	44.55%	-17.92%
ABVC	43 Neutral	$67.09M	―	-39.93%	―	186.84%	89.16%
IBIO	42 Neutral	$11.89M	―	-90.83%	―	650.00%	85.42%
ALLR	28 Underperform	$13.23M	―	-150.58%	―	―	99.59%

Marker Therapeutics Corporate Events

Marker Therapeutics Grants Stock Options to Directors

On February 12, 2024, Marker Therapeutics’ Board of Directors approved a discretionary award of 30,000 stock options to each of three non-employee directors. These stock options vest annually over three years, aligning with the company’s strategic compensation plan to incentivize leadership and potentially enhance company performance.